Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

This study tests a combination of two drugs — seclidemstat and azacitidine — for patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML), which are bone marrow disorders where blood cells don't develop properly. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with MDS or CMML classified as intermediate or high risk - Your MDS or CMML has come back or stopped responding to previous treatment with azacitidine or a similar drug - You have adequate organ function **You may NOT be eligible if...** - You have had a bone marrow/stem cell transplant recently - You have active serious infection or uncontrolled medical conditions - You are pregnant or breastfeeding - You have leukemia that has transformed to acute myeloid leukemia (AML) Talk to your doctor to see if this trial is right for you.